RareCan, the UK’s only health tech company that specialises in supporting people with rare cancers, has been selected to join the prestigious KQ Labs programme run by the world renowned Francis Crick Institute in London. KQ Labs is an accelerator programme for exciting early-stage start-ups using data as a core part of their business model to improve human health. 

RareCan use clinical, histological and genetic characterisation of its members’ cancers to provide personalised tools to better understand and live well with a rare cancer diagnosis; and to provide a suite of research services to academic and pharmaceutical industry clients.

Piers Kotting, co-founder and Chief Executive Officer at RareCan, said: “We are hugely excited by the opportunities the programme offers RareCan to evolve its data science.  We will be leveraging the expertise at the Crick Institute and its partners in the programme, to develop data science driven tools for our members with cancer, and for our academic and pharmaceutical industry clients, initially aimed at accelerating recruitment into trials and increasing retention.”

Mandeep Dhillon, KQ Labs Lead, said: We are excited to invite RareCan into our Cohort 5. RareCan were successful following a highly competitive process. We believe that this project has high value to rare cancer patients in the UK and globally, and we look forward to working with RareCan, which will include supporting them navigate through the Crick as well as our extensive global network (including corporates, mentors, advisors and investors)“.